Ann: Additional Phase 1 data suggest MPL may inhibit MND, page-298

Well said Lastly.

I would add that imo Doctor Mathers isn't just thinking about the dollars when she asked for an unscheduled interim analysis. I think she has taken this action also considering the cost to her in terms of precious time looking after patients, and her reputation as a renowned medical leader and professional.

I say, the faster-tracking of the Ph1/2 means a great deal to her and that team ... faster means doing good sooner for many who don't have time. That is what they care about most ... they are professionals after all.

One can only conclude she needs the measured scientific conclusions for the improvements she is seeing. Only then can she speak with professional confidence and advocate for faster next steps.

PAA BOD and SHs are on a unity ticket, because her work and subsequent positive advocacy will be taken very seriously by everyone, and that will unlock much much more opportunity ... Ph2, FDA, TGA, re-rate, funds, cancer targets etc.

GLTAH
QQ